Intercept Pharmaceuticals Inc

Intercept Pharmaceuticals — J.P. Morgan Healthcare Conference 2023

23 slides from Intercept Pharmaceuticals's conference presentation, Jan 11, 2023

  1. Slide 1: Intercept Pharmaceuticals J.P. Morgan Healthcare Conference

    Slide 1: Intercept Pharmaceuticals J.P. Morgan Healthcare Conference

    Intercept Pharmaceuticals J.P. Morgan Healthcare Conference Jerry Durso, President and CEO January 12, 2023

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Slide 2: Cautionary Note Regarding Forward-Looking Statements

    This presentation is intended for investor purposes only and is not intended for promotional purposes. 2 Cautionary Note Regarding Forward - Looking Statements ("FLS") This document contains FLS, including regarding : our finances, financial guidance, and financial results, including expectations re

  3. Slide 3: Our mission is to build a healthier tomorrow for people with progressive non-viral liver diseases

    Slide 3: Our mission is to build a healthier tomorrow for people with progressive non-viral liver diseases

    Our mission is to build a healthier tomorrow for people with progressive non - viral liver diseases

  4. Slide 4: Intercept Today: Established Expertise in Liver Disease

    Slide 4: Intercept Today: Established Expertise in Liver Disease

    Intercept Today: Established Expertise in Liver Disease 4 This presentation is intended for investor purposes only and is not intended for promotional purposes. Sustainable and growing PBC business with Ocaliva Fully integrated organization with ~350 employees focused exclusively in liver disease St

  5. Slide 5: Strong Financial Foundation for Future Growth and Success

    Slide 5: Strong Financial Foundation for Future Growth and Success

    Strong Financial Foundation for Future Growth and Success 5 This presentation is intended for investor purposes only and is not intended for promotional purposes. 2022 Actions and Select Financial Results Impact in 2023 • $450M sale of rights to Ocaliva in PBC outside the U.S. • $389M 2026 convertib

  6. Slide 6: Sustainable and Growing PBC Business with Ocaliva

    Slide 6: Sustainable and Growing PBC Business with Ocaliva

    Progressing OCA for Pre - Cirrhotic Liver Fibrosis due to NASH Advancing Internal Pipeline, 2023 Priorities Jennie, Living with PBC Sustainable and Growing PBC Business with Ocaliva

  7. Slide 7: Ocaliva in PBC – A Strong Foundational Business

    Slide 7: Ocaliva in PBC – A Strong Foundational Business

    Ocaliva is approved for the treatment of PBC* in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA Ocaliva in PBC – A Strong Foundational Business 7 This presentation is intended for investor purposes only

  8. Slide 8: Our Ocaliva Business Shows Strong Growth in 2022

    Slide 8: Our Ocaliva Business Shows Strong Growth in 2022

    Our Ocaliva Business Shows Strong Growth in 2022 (Unaudited) This presentation is intended for investor purposes only and is not intended for promotional purposes. 0 50 100 150 200 250 300 2016 2017 2018 2019 2020 2021 2022 Millions (USD) U.S. Ocaliva Net Sales ~10% growth 8 ~$285M NS0 JD1 KP2 NS3

  9. Slide 9: Pathway for Long-Term Ocaliva Growth

    Slide 9: Pathway for Long-Term Ocaliva Growth

    >60% 85% ~90% 89% Pathway for Long - Term Ocaliva Growth This presentation is intended for investor purposes only and is not intended for promotional purposes. Demonstrating a need to go beyond ALP management in fully addressing PBC treatment 9% increase in first - time writers (Rx) in 2022 vs. 2021

  10. Slide 10: Data Demonstrates Long-Term Improved Clinical Outcomes in Patients Taking OCA for PBC

    Slide 10: Data Demonstrates Long-Term Improved Clinical Outcomes in Patients Taking OCA for PBC

    A 70% lower risk of death or liver transplant compared to control patients was demonstrated in a key publication in Gastroenterology 1 Data Demonstrates Long - Term Improved Clinical Outcomes in Patients Taking OCA for PBC 10 This presentation is intended for investor purposes only and is not intend

  11. Slide 11: Fixed-Dose Combination of OCA+Bezafibrate May Establish New Best-in-Class Clinical Benefits

    Slide 11: Fixed-Dose Combination of OCA+Bezafibrate May Establish New Best-in-Class Clinical Benefits

    Fixed - Dose Combination of OCA+Bezafibrate May Establish New Best - in - Class Clinical Benefits 11 This presentation is intended for investor purposes only and is not intended for promotional purposes. Exploring the potential for improved efficacy and tolerability with a fixed - dose combination o

  12. Slide 12: Progressing OCA for Pre-Cirrhotic Liver Fibrosis due to NASH

    Slide 12: Progressing OCA for Pre-Cirrhotic Liver Fibrosis due to NASH

    Sustainable and Growing PBC Business with Ocaliva Terri, Living with Advanced Fibrosis due to NASH Progressing OCA for Pre - Cirrhotic Liver Fibrosis due to NASH Advancing Internal Pipeline, 2023 Priorities

  13. Slide 13: OCA: Unique Opportunity To Help NASH Patients With Pre-Cirrhotic Fibrosis

    Slide 13: OCA: Unique Opportunity To Help NASH Patients With Pre-Cirrhotic Fibrosis

    OCA: Unique Opportunity To Help NASH Patients With Pre - Cirrhotic Fibrosis due to NASH 13 This presentation is intended for investor purposes only and is not intended for promotional purposes. NDA re - submitted in December 2022; anticipating a PDUFA target review time of six months OCA is an antif

  14. Slide 14: Reaching Patients with OCA at a Pivotal Point in NASH Disease Progression

    Slide 14: Reaching Patients with OCA at a Pivotal Point in NASH Disease Progression

    Reaching Patients with OCA at a Pivotal Point in NASH Disease Progression 14 This presentation is intended for investor purposes only and is not intended for promotional purposes. • Predominantly managed in primary care • Focus on screening for fibrosis in at - risk populations • Treatment goals are

  15. Slide 15: REGENERATE: Largest and Longest-Running Pivotal Phase 3 Study in Fibrosis Due to NASH

    Slide 15: REGENERATE: Largest and Longest-Running Pivotal Phase 3 Study in Fibrosis Due to NASH

    REGENERATE: The First, Largest and Longest - Running Pivotal Phase 3 Study in Patients With Fibrosis Due to NASH Achieved its Primary Endpoint in Two Analyses 15 This presentation is intended for investor purposes only and is not intended for promotional purposes. PATIENT POPULATION 2,480 patients w

  16. Slide 16: OCA Demonstrated Strong Antifibrotic Effect and Manageable Safety Profile

    Slide 16: OCA Demonstrated Strong Antifibrotic Effect and Manageable Safety Profile

    OCA Demonstrated Strong Antifibrotic Effect and Monitorable and Manageable Safety Profile 16 This presentation is intended for investor purposes only and is not intended for promotional purposes. Robust safety assessment of 2,477 patients, including 1,000 on study drug for four years demonstrated a

  17. Slide 17: Intercept Is Poised To Deliver OCA in NASH Upon Approval

    Slide 17: Intercept Is Poised To Deliver OCA in NASH Upon Approval

    Intercept Is Poised To Deliver OCA in NASH Upon Approval 17 This presentation is intended for investor purposes only and is not intended for promotional purposes. of highest potential Heps/GIs are within our existing PBC customer base Established U.S. field presence with broad geographic footprint •

  18. Slide 18: Advancing Internal Pipeline, 2023 Priorities

    Slide 18: Advancing Internal Pipeline, 2023 Priorities

    Sustainable and Growing PBC Business with Ocaliva Progressing OCA for Pre - Cirrhotic Liver Fibrosis due to NASH Advancing Internal Pipeline, 2023 Priorities

  19. Slide 19: Clinical Development Programs

    Slide 19: Clinical Development Programs

    Clinical Development Programs 19 This presentation is intended for investor purposes only and is not intended for promotional purposes. *Currently used for investigational purposes only. Has not been approved by the FDA or any other worldwide regulatory agency. Sa fety and efficacy have not been est

  20. Slide 20: Advancing INT-787 in Lead Indication: Severe Alcohol-Associated Hepatitis

    Slide 20: Advancing INT-787 in Lead Indication: Severe Alcohol-Associated Hepatitis

    Advancing INT - 787 in Lead Indication: Severe Alcohol - Associated Hepatitis 20 This presentation is intended for investor purposes only and is not intended for promotional purposes. Alcohol - related liver disease is currently the leading indication for liver transplant listing in the U.S., with a

  21. Slide 21: 2023 Strategic Priorities: Building on Strong Foundation in Liver Disease

    Slide 21: 2023 Strategic Priorities: Building on Strong Foundation in Liver Disease

    2023 Strategic Priorities: Building on Strong Foundation in Liver Disease This presentation is intended for investor purposes only and is not intended for promotional purposes. 21 Gain FDA approval for OCA in NASH Advance internal pipeline in liver diseases with high unmet need Continue to maintain

  22. Slide 22: Appendix

    Slide 22: Appendix

    Appendix Intercept |J

  23. Slide 23: Q4 and FY 2022 Financial Highlights / Reconciliation of Non-GAAP Adjusted Net Sales

    Slide 23: Q4 and FY 2022 Financial Highlights / Reconciliation of Non-GAAP Adjusted Net Sales

    Q4 and FY 2022 Financial Highlights / Reconciliation of Non - GAAP Adjusted Net Sales To Total Revenue (Unaudited) 23 This presentation is intended for investor purposes only and is not intended for promotional purposes. Three Months Ended December 31, Twelve Months Ended December 31, 2022 2021 2022

Source: SEC EDGAR · 8-K filed Jan 11, 2023

More decks from Intercept Pharmaceuticals Inc